Identifying metabolic alterations in newly diagnosed small cell lung cancer patients.

ABSTRACT:

Background

Small cell lung cancer (SCLC) is a malignant disease with poor prognosis. At the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is based on imaging, histopathology, and immunohistochemistry, but no blood-based biomarkers have yet proven to be clinically successful for diagnosis and screening. The precise mechanisms of SCLC are not fully understood, however, several genetic mutations, protein and metabolic aberrations have been described. We aim at identifying metabolite alterations related to SCLC and to expand our knowledge relating to this aggressive cancer.

Methods

A total of 30 serum samples of patients with SCLC, collected at the time of diagnosis, and 25 samples of healthy controls were included in this study. The sample

SUBMITTER: Pedersen S 

PROVIDER: S-EPMC8455369 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature